Erythromycin is no longer scarce

Business News Agency January 2 News In the past year, the supply of erythromycin injections (hereinafter referred to as erythromycin) has sharply decreased in the market. The underlying reason is that, as the drug is listed in the National Essential Drug List, its price has been strictly controlled, with a clinical price of 1.5 yuan per bottle, which has caused the profitability of drug companies to be greatly reduced, and companies have lost their enthusiasm for production. From August this year, the parties concerned resumed the daily production and supply of the drug.

Why are cheap drugs disappearing? According to China's current drug price management system, there are three forms of drug prices: 1. The drugs that are purchased by finance and distributed to specific people free of charge are subject to government pricing. Currently, there are about 100 kinds of medicines, accounting for about 0.8% of the quantities of drugs that have been approved for listing. 2. Medicare drugs are subject to government guidance prices, in the form of the maximum retail price limit, which is about 2600 kinds, accounting for about 22%. 3. The market-adjusted drugs are priced independently by the companies, accounting for about 77%. The basic drug system introduced by the state is largely to protect cheap drugs. However, this system has only completed the work of setting up catalogues. Follow-up production, distribution, prices, and use are still far from perfect. It will cause cheap medicine to "disappear".

At 9 o'clock in the morning on December 27th, the daughter of Liu Zhien with a cold in Shenhe District visited the Shenzhou Hospital for medical treatment. About half an hour later, the little guy quietly sat in a chair and infused. Liu Zhien said that her daughter is ill in the winter and last year was also a pneumonia attack. The city was looking for erythromycin, and major hospitals had no medicine. No longer scarce erythromycin on the 27th, the reporter visited a number of hospitals in Shenyang, erythromycin injection can basically meet the clinical needs, the phenomenon of erythromycin scarcity for a year has been basically eased. According to Chen Hong, deputy director of the Shenzhou Hospital, in her memory, the relevant departments have implemented the supply of erythromycin, and the daily supply has been guaranteed since the last three months. Dr. Feng of the Department of Pharmacy of the First Affiliated Hospital of China Medical University stated that although there was a small amount of erythromycin in the hospital before, it could not meet the supply and it has now been able to guarantee clinical practice. Li Shihai, general manager of Dalian Meiluo Pharmaceutical Co., once told reporters that for a long period of time, the price of erythromycin in the “black market” was fired to more than 10 yuan per piece.

On December 26, the reporter made an unannounced visit to Shenyang Nanliu and found that erythromycin was no longer the drug that hoarders had hoarded. The erythromycin hospital referred to erythromycin, we must mention Shenyang Weikang Hospital. After May of this year, Shenyang Weikang Hospital almost monopolized the sales of erythromycin in the region, and sold each patient at a price higher than the price of the basic medicine list. At the same time, it was limited to use in this hospital. Thanks to the role of erythromycin, Weikang Hospital, especially the paediatric ward, did achieve the "full-blown child" scene, which also made this newly opened private hospital quickly occupy the "popularity." In August this year, after the report of the newspaper on erythromycin was reported, relevant departments conducted investigations on the “unauthorized increase of the selling price of erythromycin” at Weikang Hospital. Subsequently, Weikang Hospital lowered the clinical sales price of the drug.

On December 23, the reporter once again came to Wellcome Hospital and found that the price of erythromycin in the hospital had been restored to the price level specified in the Essential Drug Directory. One person in the industry believes that, despite being punished, from a marketing point of view, the positive impact of the erythromycin stock-out event on Weikang Hospital is far greater than the negative effects of media exposure and punishment. After the recovery of production, the manufacturers’ helplessness led to a serious shortage of erythromycin in the national market this year. This is because the manufacturer of the drug has reduced production. In August this year, the reporter went to the nation’s largest erythromycin production company, Dalian Metropolitan, to conduct an interview. It was learned that the original Meilu Pharmaceutical's ability to produce erythromycin was 45 million, accounting for more than 90% of the national market. However, after the drug's clinical sales price fell by a hair, the company has reduced the production of erythromycin to 1.5 million per month. At that time, Dalian Meiluo had submitted a price increase application to the National Development and Reform Commission. The price increase for its application was a single erythromycin price increase of 0.5 yuan.

On December 26, the reporter once again contacted Li Shihai, general manager of the company, on this issue. Li Shihai said that the company has resumed production, and as to whether its application for price increases submitted by the National Development and Reform Commission was approved, Li Shihai did not make a clear reply. Between words, Li Shihai showed a little helplessness: the output was restored to the past, and the price did not have any Variety. There is no optimistic market outlook but market inventories are still in crisis.

On December 26th, Mr. Liu, a person in charge of a drug sales company in Liaoning, said that the serious shortage of goods in the previous period resulted in insufficient inventory of erythromycin. Mr. Liu said that under normal circumstances, the drug's stock period is to ensure the supply of 20 days, and now there is only one week of supply. Also worried about erythromycin is the director of the pharmacy department of the First Affiliated Hospital of China Medical University.

On December 27th, she told reporters that at present, erythromycin has no profit in circulation, and it is almost how much money the drug company gives to its distributors. How much money does the distributor give to the hospital, including some hospitals including the hospital? No more markups, sell them to patients directly. "This is not a normal market behavior." Director Feng said that in order to ensure compliance with the prices stipulated by the National Development and Reform Commission, several compromises must be made. Otherwise, the problem of missing erythromycin will be repeated. The collective drugs of low-cost drugs are not just erythromycin. Currently, there are many kinds of low-cost, practical, and efficient drugs in the basic drug list that face the same predicament. Director Feng told the reporter that there is also a drug called glycyl alcohol. The sales price is about 3 bucks because the company has no profit, and now it basically stops production. Feng Feng said that the purpose of price control of essential medicines by the state is to protect the interests of patients to the maximum extent possible. However, the reality is that “there is a trade-off between them.” Once the company is no longer producing, patients must use expensive medicines instead. Zhou Yan, secretary general of the China Chemical Pharmaceutical Industry Association, found a strange phenomenon in the investigation. In the procurement process of essential medicines in Anhui Province, all successful pharmaceutical manufacturers were small enterprises, and none of the large pharmaceutical companies won the bid. “This has shown that the production enthusiasm of big companies has begun to cool.” Zhou Yan said that the government is the greatest coordinator and balancer of the interests of all parties. As for how to balance, it is also a science.

This project Gannan quality navel orange whole fruit (not peeled) as raw materials, using self-developed patent Orange surface sterilization technology to maximize retained a whole pieces of all Orange essence (Orange: Shun Qi, phlegm, pulp: fiber laxative, fruit seeds: allergic inflammation, juice: whitening detox).

Conventional enzyme production is mainly produced by hand, hand-sliced, hand-fermentation, the company every step of the process are used self-developed technology and equipment to automate production. Moreover, the conventional enzyme production have adopted a fermentation technology, enzyme often taste discomfort, sour and other issues, I produced using a variety of enzymes, probiotics composite grade fermentation technology, fermentation at different times with different strains, and two or three times through fermentation, enzymes such pure taste, streptozotocin balanced nutrients. Scientific and standardized process:

I produced using enzymes navel cleaning, sterilization, slice, fermentation (fermentation grade composite multi-strain), solid-liquid separation, bottling and other steps. Each step developed a patented automated production equipment, fully automated production, to avoid the traditional manual production workers are not standardized, easy to pollution, low production efficiency, product quality is unstable defects.

Companies registered capital of 35 million yuan, the end of 2014 the total assets of 48.69 million yuan, including fixed assets of 37.52 million yuan. The company's existing cooperation Orange cultivation base 7043.5 acres, the company production base is located in Jiangxi County Tech Industrial Park Chu Tan industrial area, covers an area of 120 acres, it has built a standard plant 9,000 square meters, Nissan 6000 kg Orange enzymes and other liquid enzyme products. Enzyme, known as enzyme, refers to a polymer substance having biocatalytic functionality. In the catalytic reaction system an enzyme, the reactant molecules are known as substrates, enzyme substrates by catalytic conversion to another molecule. Almost all cellular activity of enzymes involved in the process are required to improve efficiency. Similar to other non-biological catalysts, enzymes chemical reactions by lowering the activation energy to accelerate the rate of the reaction, most of the enzyme catalyzed reaction rate can be increased a million times; in fact, the enzyme is to provide an activation energy needs than another low way, so that more particles to have less than the activation energy of the reaction kinetic energy, thus speeding up the reaction rate. Enzyme as a catalyst, in itself is not consumed during the reaction, it does not affect the chemical equilibrium reactions. Positive enzyme catalysis, but also a negative catalytic effect, not only to accelerate the reaction rate, but also to reduce the reaction rate. And other non-living catalysts is different, having a high degree of specificity of enzyme, only a catalytic reaction or produce a particular specific configuration.

Orange Enzyme Solution

Orange Enzyme Solution,Enzyme Essence Liquid,Fresh Orange Fermentation

Ganzhou Green days Biochemical Technology Co., Ltd. , http://www.cn-gangdao.com